Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noradrenaline versus midodrine + octreotide for type 1 hepatorenal syndrome
IRCT20230228057568N1Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Mar 2023
- Modality
- Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatorenal syndrome (HRS) comparing Midodrine + octreotide + albumin with Noradrenaline + albumin (2 arms). Primary endpoint: Treatment of hepatorenal syndrome. Started Mar 2023; status: completed.
02
Drugs
norepinephrinemidodrineoctreotidealbumin (human)
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on IRCT20230228057568N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230228057568N1.